Amylyx Pharmaceuticals (AMLX) Operating Income (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Operating Income of -$43.8 million for Q1 2026, down 15.81% year-over-year from -$52.0 million in Q1 2025, and down 19.6% quarter-over-quarter from -$36.6 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Operating Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Operating Income history runs 6 years deep, the most recent figure standing at -$43.8 million for Q1 2026.
- In Q1 2026, Operating Income fell 15.81% year-over-year to -$43.8 million; the TTM figure through Mar 2026 stood at -$159.3 million (up 30.87% YoY), while the FY2025 annual figure was -$153.3 million, up 51.29% from the prior year.
- Operating Income for Q1 2026 stood at -$43.8 million, down from -$36.6 million in the prior quarter.
- The five-year high for Operating Income was $20.2 million in Q2 2023, with the low at -$122.1 million in Q1 2024.
- The 5-year median for Operating Income is -$42.9 million (2025), against an average of -$39.7 million.
- The sharpest annual moves came in 2023 and 2024: Operating Income soared 137.23% in 2023, then slumped 5848.86% in 2024.
- Amylyx Pharmaceuticals' Operating Income stood at -$44.6 million in 2022, then jumped by 104.34% to $1.9 million in 2023, then sank by 2202.07% to -$40.7 million in 2024, then climbed by 9.96% to -$36.6 million in 2025, then dropped by 19.6% to -$43.8 million in 2026.
- Business Quant data shows AMLX's Operating Income at -$43.8 million in Q1 2026, -$36.6 million in Q4 2025, and -$36.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 953.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 9.00 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 248.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | -45.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.69 Mn |
| Mar 31, 2026 | -43.78 Mn |
| Dec 31, 2025 | -36.61 Mn |
| Sep 30, 2025 | -36.03 Mn |
| Jun 30, 2025 | -42.86 Mn |
| Mar 31, 2025 | -37.80 Mn |
| Dec 31, 2024 | -40.65 Mn |
| Sep 30, 2024 | -75.66 Mn |
| Jun 30, 2024 | -76.29 Mn |
| Mar 31, 2024 | -122.13 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 18.72 Mn |
| Jun 30, 2023 | 20.20 Mn |
| Mar 31, 2023 | -2.05 Mn |
| Dec 31, 2022 | -44.59 Mn |
| Sep 30, 2022 | -54.68 Mn |
| Jun 30, 2022 | -54.25 Mn |
| Mar 31, 2022 | -47.81 Mn |
| Dec 31, 2021 | -28.32 Mn |
| Sep 30, 2021 | -22.92 Mn |